|
x
|
Annual
report pursuant to Section 15(d) of the Securities Exchange Act of
1934
|
|
o
|
Transition
report pursuant to Section 15(d) of the Securities Exchange Act of
1934
|
|
A.
|
Full
title of the plan and the address of the plan, if different from
that of
the issuer named below:
|
|
B.
|
Name
of issuer of the securities held pursuant to the plan and the address
of
its principal executive office:
|
Report
of Ernst & Young LLP, Independent Registered Public
Accounting Firm
|
1
|
|
|
Audited
Financial Statements
|
|
|
|
Statements
of Net Assets Available for Plan Benefits
|
2
|
Statement
of Changes in Net Assets Available for Plan Benefits
|
3
|
Notes
to the Financial Statements
|
4-10
|
|
|
Supplemental
Schedule
|
|
|
|
Schedule
H, Line 4i - Schedule of Assets (Held at End of Year)
|
11
|
|
/s/ Ernst & Young LLP |
December
31
|
||||||||
2006
|
2005
|
|||||||
Assets
|
||||||||
Investments
(at fair value)
|
$ |
829,374,528
|
$ |
706,304,215
|
||||
Receivables:
|
||||||||
Participant
contributions
|
1,995,760
|
—
|
||||||
Employer
contribution
|
5,084,094
|
3,229,817
|
||||||
Total
receivables
|
7,079,854
|
3,229,817
|
||||||
Net
assets reflecting all investments at fair value
|
836,454,382
|
709,534,032
|
||||||
Adjustment
from fair value to contract value for
|
||||||||
fully
benefit-responsive investment contracts
|
827,739
|
1,013,100
|
||||||
Net
assets available for plan benefits
|
$ |
837,282,121
|
$ |
710,547,132
|
||||
Additions
to net assets attributed to:
|
||||
Investment
Income:
|
||||
Interest
|
$ |
4,713,988
|
||
Dividends
|
34,164,826
|
|||
38,878,814
|
||||
Contributions:
|
||||
Participants
|
65,690,691
|
|||
Employer
|
45,448,217
|
|||
Participant
rollovers
|
8,675,552
|
|||
119,814,460
|
||||
Assets
transferred in
|
25,350,767
|
|||
Total
additions
|
184,044,041
|
|||
Deductions
from net assets attributed to:
|
||||
Benefits
paid to participants
|
56,363,380
|
|||
Net
depreciation in fair value of investments
|
873,572
|
|||
Service
fees
|
72,100
|
|||
Total
deductions
|
57,309,052
|
|||
Net
increase
|
126,734,989
|
|||
Net
assets available for plan benefits:
|
||||
Beginning
of year
|
710,547,132
|
|||
End
of year
|
$ |
837,282,121
|
||
1.
|
DESCRIPTION
OF THE PLAN
|
1.
|
DESCRIPTION
OF THE PLAN (CONTINUED)
|
1.
|
DESCRIPTION
OF THE PLAN (CONTINUED)
|
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING
POLICIES
|
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
|
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
(CONTINUED)
|
3.
|
INVESTMENTS
|
December
31,
|
||||||||
2006
|
2005
|
|||||||
Vanguard
500 Index Fund Investor Shares
|
$ |
141,589,359
|
$ |
118,738,001
|
||||
Boston
Scientific Corporation Common Stock Fund
|
107,145,255
|
137,925,737
|
||||||
Vanguard
Wellington Fund Investor Shares
|
95,381,059
|
72,391,531
|
||||||
Vanguard
International Growth Fund
|
89,829,791
|
56,410,055
|
||||||
Vanguard
Retirement Savings Trust
|
86,847,565
|
77,835,142
|
||||||
Vanguard
Windsor II Fund Investor Shares
|
83,288,037
|
62,748,581
|
||||||
Vanguard
Growth Index Fund Investor Shares
|
76,665,824
|
63,995,486
|
||||||
Vanguard
Mid-Cap Growth Fund
|
47,439,879
|
*
|
||||||
Vanguard
Total Bond Market Index Fund
|
43,162,805
|
35,626,288
|
Mutual
funds
|
$ |
41,347,695
|
||||||
Common
stock
|
(42,221,267 | ) | ||||||
$ | (873,572 | ) |
|
4.
|
TRANSACTIONS
WITH PARTIES-IN-INTEREST
|
4.
|
TRANSACTIONS
WITH PARTIES-IN-INTEREST
(CONTINUED)
|
5.
|
RISKS
AND UNCERTAINTIES
|
6.
|
INCOME
TAX STATUS
|
7.
|
RECONCILIATION
OF FINANCIAL STATEMENTS TO FORM
5500
|
December
31,
|
||||||||
2006
|
2005
|
|||||||
Net
assets available for plan benefits per the financial
|
||||||||
statements
|
$ |
837,282,121
|
$ |
710,547,132
|
||||
Less: Adjustment
from fair value to contract
|
||||||||
value for fully benefit responsive
|
||||||||
investment contracts
|
(827,739 | ) |
—
|
|||||
Deemed
distributions
|
(2,172 | ) | (11,885 | ) | ||||
Net
assets available for plan benefits per the 5500
|
836,452,210
|
710,535,247
|
8.
|
SUBSEQUENT
EVENTS
|
Current
|
||||||||
Identity
of Issue
|
Shares
or Units
|
Value
|
||||||
*
Vanguard Group:
|
||||||||
500
Index Fund Investor Shares
|
1,084,228
|
141,589,359
|
||||||
Wellington
Fund Investor Shares
|
2,941,137
|
95,381,059
|
||||||
International
Growth Fund
|
3,764,869
|
89,829,791
|
||||||
Retirement
Savings Trust
|
86,847,565
|
86,019,826
|
||||||
Windsor
II Fund Investor Shares
|
2,396,778
|
83,288,037
|
||||||
Growth
Index Fund Investor Shares
|
2,575,271
|
76,665,824
|
||||||
Mid-Cap
Growth Fund
|
2,779,138
|
47,439,879
|
||||||
Total
Bond Market Index Fund
|
4,320,601
|
43,162,805
|
||||||
*
Boston Scientific Corporation Common Stock Fund
|
6,236,627
|
107,145,255
|
||||||
Pfizer
Common Stock Fund
|
285,792
|
7,402,008
|
||||||
T.
Rowe Price Small-Cap Stock Fund-Advisor Class
|
965,262
|
32,876,812
|
||||||
*
Participants’ notes receivable 5.00% - 10.75%
|
18,573,873
|
|||||||
$ |
829,374,528
|
|||||||
Boston Scientific
Corporation
401(k) Retirement Savings Plan
|
|||
Date: June
28, 2007
|
By:
|
/s/ Jamie Rubin | |
Jamie Rubin | |||
Member, 401(k) Plan Administrative and Investment Committee | |||
Exhibit Number | Description |
23
|
Consent
of Independent Auditors
|